Grégory Camus

3.1k total citations
32 papers, 1.1k citations indexed

About

Grégory Camus is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Grégory Camus has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hepatology, 14 papers in Epidemiology and 12 papers in Infectious Diseases. Recurrent topics in Grégory Camus's work include Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (11 papers) and HIV/AIDS drug development and treatment (7 papers). Grégory Camus is often cited by papers focused on Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (11 papers) and HIV/AIDS drug development and treatment (7 papers). Grégory Camus collaborates with scholars based in United States, France and Germany. Grégory Camus's co-authors include Clarisse Berlioz‐Torrent, Mélanie Ott, Eva Herker, Sandra López‐Vergès, Richard Bénarous, Guillaume Blot, Robert V. Farese, Warner C. Greene, Joel T. Haas and Édouard Bertrand and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Grégory Camus

32 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Grégory Camus United States 17 490 455 312 288 270 32 1.1k
Gabrielle Vièyres Germany 20 663 1.4× 883 1.9× 182 0.6× 162 0.6× 296 1.1× 31 1.4k
Christophe Hourioux France 19 815 1.7× 727 1.6× 194 0.6× 119 0.4× 217 0.8× 32 1.1k
Olivier Diaz France 18 596 1.2× 405 0.9× 118 0.4× 68 0.2× 335 1.2× 30 1.2k
Yutaka Amako United States 11 338 0.7× 384 0.8× 75 0.2× 80 0.3× 251 0.9× 13 781
Takahiro Masaki Japan 22 775 1.6× 943 2.1× 146 0.5× 115 0.4× 641 2.4× 59 1.7k
Rongjuan Pei China 20 464 0.9× 403 0.9× 158 0.5× 71 0.2× 312 1.2× 36 866
Malika Ait‐Goughoulte France 17 788 1.6× 655 1.4× 111 0.4× 57 0.2× 169 0.6× 25 1.1k
Patrick Labonté Canada 14 446 0.9× 303 0.7× 124 0.4× 57 0.2× 213 0.8× 35 839
C Bréchot France 14 1.2k 2.5× 1.4k 3.1× 79 0.3× 70 0.2× 275 1.0× 36 1.7k
Daniel J. Felmlee United Kingdom 17 735 1.5× 818 1.8× 88 0.3× 70 0.2× 129 0.5× 34 1.0k

Countries citing papers authored by Grégory Camus

Since Specialization
Citations

This map shows the geographic impact of Grégory Camus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grégory Camus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grégory Camus more than expected).

Fields of papers citing papers by Grégory Camus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grégory Camus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grégory Camus. The network helps show where Grégory Camus may publish in the future.

Co-authorship network of co-authors of Grégory Camus

This figure shows the co-authorship network connecting the top 25 collaborators of Grégory Camus. A scholar is included among the top collaborators of Grégory Camus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grégory Camus. Grégory Camus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Asselah, Tarik, Michael A. Chattergoon, Alina Jucov, et al.. (2025). A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D. New England Journal of Medicine. 394(4). 343–353. 1 indexed citations
2.
Li, Jiani, Ross Martin, Dong Han, et al.. (2024). SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants. Antimicrobial Agents and Chemotherapy. 69(2). e0123824–e0123824. 2 indexed citations
3.
Bauer, Rebecca N., Anastasia Teterina, Haridha Shivram, et al.. (2023). Prognostic value of severe acute respiratory syndrome coronavirus‐2 viral load and antibodies in patients hospitalized with COVID‐19. Clinical and Translational Science. 16(6). 1049–1062. 6 indexed citations
4.
Hedskog, Charlotte, Lauren Rodriguez, Pavitra Roychoudhury, et al.. (2023). Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1). The Journal of Infectious Diseases. 228(9). 1263–1273. 17 indexed citations
5.
Choi, Hosoon, et al.. (2022). Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection. Open Forum Infectious Diseases. 9(8). ofac382–ofac382. 19 indexed citations
6.
Pitts, Jared, Jiani Li, Jason K. Perry, et al.. (2022). Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. Antimicrobial Agents and Chemotherapy. 66(6). e0022222–e0022222. 48 indexed citations
7.
Gupta, Neil, Fabienne Shumbusho, Janvier Serumondo, et al.. (2022). Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. ˜The œLancet. Gastroenterology & hepatology. 7(6). 542–551. 15 indexed citations
8.
Kateera, Fredrick, Fabienne Shumbusho, Janvier Serumondo, et al.. (2022). Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial. ˜The œLancet. Gastroenterology & hepatology. 7(6). 533–541. 9 indexed citations
9.
Sood, Ajit, Ajay Duseja, Abhijit Chowdhury, et al.. (2019). Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. Hepatology International. 13(2). 173–179. 14 indexed citations
10.
Sarrazin, Christoph, Curtis Cooper, Michael P. Manns, et al.. (2018). No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. Journal of Hepatology. 69(6). 1221–1230. 41 indexed citations
11.
Camus, Grégory, Simin Xu, Bin Han, et al.. (2017). Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems. Virology. 514. 134–141. 11 indexed citations
12.
Boehm, Daniela, Grégory Camus, Andrea Gramatica, et al.. (2017). SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency. Cell Host & Microbe. 21(5). 569–579.e6. 80 indexed citations
13.
Camus, Grégory, Martina Schweiger, Eva Herker, et al.. (2014). The Hepatitis C Virus Core Protein Inhibits Adipose Triglyceride Lipase (ATGL)-mediated Lipid Mobilization and Enhances the ATGL Interaction with Comparative Gene Identification 58 (CGI-58) and Lipid Droplets. Journal of Biological Chemistry. 289(52). 35770–35780. 30 indexed citations
14.
Camus, Grégory, Eva Herker, Brian Webster, et al.. (2013). Lipid Droplet-Binding Protein TIP47 Regulates Hepatitis C Virus RNA Replication through Interaction with the Viral NS5A Protein. PLoS Pathogens. 9(4). e1003302–e1003302. 95 indexed citations
15.
Camus, Grégory, Eva Herker, Joel T. Haas, et al.. (2013). Diacylglycerol Acyltransferase-1 Localizes Hepatitis C Virus NS5A Protein to Lipid Droplets and Enhances NS5A Interaction with the Viral Capsid Core. Journal of Biological Chemistry. 288(14). 9915–9923. 112 indexed citations
16.
Janvier, Katy, et al.. (2011). Rab7A Is Required for Efficient Production of Infectious HIV-1. PLoS Pathogens. 7(11). e1002347–e1002347. 51 indexed citations
17.
Molle, Dorothée, Carolina Segura-Morales, Grégory Camus, et al.. (2009). Endosomal Trafficking of HIV-1 Gag and Genomic RNAs Regulates Viral Egress. Journal of Biological Chemistry. 284(29). 19727–19743. 50 indexed citations
18.
Camus, Grégory, et al.. (2008). Enfermedad celiaca asociada a síndrome antifosfolípido. Revista Española de Enfermedades Digestivas. 100(2). 102–3. 6 indexed citations
19.
Camus, Grégory, Carolina Segura-Morales, Dorothée Molle, et al.. (2007). The Clathrin Adaptor Complex AP-1 Binds HIV-1 and MLV Gag and Facilitates Their Budding. Molecular Biology of the Cell. 18(8). 3193–3203. 85 indexed citations
20.
López‐Vergès, Sandra, et al.. (2006). Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. Proceedings of the National Academy of Sciences. 103(40). 14947–14952. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabrielle Vièyres Breakdown of academic impact, for papers by Christophe Hourioux Breakdown of academic impact, for papers by Olivier Diaz Breakdown of academic impact, for papers by Yutaka Amako Breakdown of academic impact, for papers by Takahiro Masaki Breakdown of academic impact, for papers by Rongjuan Pei Breakdown of academic impact, for papers by Malika Ait‐Goughoulte Breakdown of academic impact, for papers by Patrick Labonté Breakdown of academic impact, for papers by C Bréchot Breakdown of academic impact, for papers by Daniel J. Felmlee
Rankless by CCL
2026